Eisai projects 42.5B yen global revenue for LEQEMBI in FY2024 amid pathway expansion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 08 2025
0mins
Should l Buy ?
Source: SeekingAlpha
Earnings Performance: Eisai Co., Ltd. reported a 9% year-on-year revenue increase to 601.2 billion yen in Q3 2024, driven by strong sales of LEQEMBI, Lenvima, and Dayvigo, with operating profit rising 48% to 55.4 billion yen.
Future Outlook: Management reaffirmed its FY2024 revenue target for LEQEMBI at 42.5 billion yen, anticipating further growth through expanded patient access and upcoming regulatory approvals, despite acknowledging potential risks from competition and Medicare Part D redesign.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
